PERSONALIZED MEDICINE REGULATION LAW – INDIA

1. INTRODUCTION

Personalized Medicine Regulation Law refers to the legal framework governing the development, approval, prescription, manufacture and monitoring of medical treatments tailored to an individual's genetic profile, biomarkers, medical history and biological characteristics.

Personalized medicine uses technologies such as pharmacogenomics, genetic testing, molecular diagnostics, companion diagnostics, precision oncology and artificial intelligence to identify treatments suitable for particular patients.

Unlike conventional medicine, personalized medicine may involve the collection and processing of sensitive genetic information and the use of patient-specific diagnostic results to determine treatment. Consequently, it raises legal questions concerning patient consent, medical confidentiality, clinical validity, drug approval, data protection and professional negligence.

India does not have one separate comprehensive statute exclusively governing personalized medicine. Its regulation is distributed across pharmaceutical legislation, medical-device regulation, clinical-trial requirements, constitutional privacy protections and biomedical research guidelines.

2. LEGAL AND REGULATORY FRAMEWORK

A. DRUGS AND COSMETICS ACT, 1940

The Act regulates the manufacture, import, distribution and sale of drugs in India. Personalized medicines involving new pharmaceutical products must satisfy applicable quality, safety, efficacy and licensing requirements.

B. NEW DRUGS AND CLINICAL TRIALS RULES, 2019

These Rules govern clinical trials, new-drug approvals and related regulatory permissions.

Personalized therapies involving new drugs, biological products or innovative treatment approaches must comply with the applicable approval requirements.

C. MEDICAL DEVICES RULES, 2017

Genetic-testing instruments, molecular diagnostic devices and certain companion diagnostic technologies may fall within the medical-device regulatory framework.

Their classification, manufacturing, importation and licensing requirements depend on their intended purpose and applicable risk category.

D. DIGITAL PERSONAL DATA PROTECTION ACT, 2023

Personalized medicine involves extensive processing of genetic and health-related information. Identifiable digital patient information may fall within the Act's scope.

Relevant provisions include Sections 4, 5, 6 and 8, concerning lawful processing, notice, consent and obligations of Data Fiduciaries.

The Act must be read with its notified commencement schedule and the Digital Personal Data Protection Rules, 2025, because implementation is phased.

E. INDIAN COUNCIL OF MEDICAL RESEARCH GUIDELINES

ICMR's National Ethical Guidelines for Biomedical and Health Research Involving Human Participants provide important ethical standards for genetic research, informed consent, confidentiality, vulnerable participants and biological sample management.

3. REGULATORY APPROVAL AND CLINICAL VALIDATION

Personalized medicine must satisfy applicable scientific and regulatory standards before clinical use.

Important requirements include:

Demonstration of analytical validity of the diagnostic test.

Evidence of clinical validity and clinical utility.

Appropriate clinical-trial approvals where required.

Ethical review by an appropriately constituted Ethics Committee.

Validation of companion diagnostic technologies.

Evidence supporting the safety and efficacy of the associated treatment.

Proper documentation of clinical and laboratory results.

Compliance with applicable manufacturing and quality standards.

CDSCO is India's national drug regulator and performs functions relating to new-drug approvals, clinical trials, medical devices and pharmacovigilance. State licensing authorities also exercise important regulatory responsibilities. <Cite refs={["turn844786search0","turn844786search2"]}/>

4. GENETIC DATA PRIVACY AND INFORMED CONSENT

Genetic information may reveal disease susceptibility, hereditary characteristics and information relevant to biological relatives. Its collection therefore requires careful privacy protection.

Healthcare providers and testing organisations should:

Explain the purpose and scope of genetic testing.

Obtain appropriate informed consent.

Explain potential incidental findings.

Maintain patient confidentiality.

Restrict unauthorised access to genetic reports.

Establish appropriate data-retention policies.

Explain third-party sharing and research use.

Provide applicable mechanisms for withdrawal of consent and exercise of data rights.

A patient's consent to diagnostic testing should not automatically be interpreted as consent to unrelated commercial exploitation of genetic information.

5. PROFESSIONAL RESPONSIBILITY AND PATIENT SAFETY

Doctors prescribing personalized treatments must exercise reasonable professional care.

They should ensure that genetic-test results are interpreted appropriately, clinical decisions are supported by reliable evidence, and patients understand the limitations of predictive testing.

A wrong genetic interpretation, inappropriate dosage recommendation or failure to consider relevant contraindications may give rise to professional negligence where the legal requirements are established.

6. PHARMACOGENOMICS AND PRECISION ONCOLOGY REGULATION

Pharmacogenomics studies how genetic variations influence an individual's response to medicines. It may help identify appropriate drug selection, dosage requirements and potential adverse reactions.

Precision oncology uses genetic mutations and molecular biomarkers to select cancer treatments.

Regulatory concerns include:

Validation of genetic and molecular diagnostic tests.

Clinical evidence supporting biomarker-based treatment decisions.

Proper approval of targeted pharmaceutical products.

Monitoring of adverse drug reactions.

Protection of patient-specific genomic information.

Prevention of misleading claims concerning treatment effectiveness.

Where a treatment is developed for a particular molecular subgroup, its regulatory approval must be supported by the applicable scientific and clinical evidence.

7. IMPORTANT JUDICIAL DECISIONS AND CASE LAWS

There is no established Supreme Court judgment creating a separate regulatory framework specifically for personalized medicine in India. However, the following decisions establish important principles concerning medical consent, privacy, genetic information and professional liability.

1. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017) 10 SCC 1

Analogous constitutional authority.

The Supreme Court recognised privacy as a fundamental right under Article 21 and other constitutional freedoms. The judgment recognised informational privacy and individual autonomy.

Legal significance: Genetic information, patient-specific medical records and genomic datasets require appropriate privacy safeguards.

2. Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1

Direct medical-consent authority.

The Supreme Court examined the requirements of informed consent in medical treatment. It held that valid consent requires adequate information concerning the nature and purpose of the proposed treatment.

Legal significance: Doctors using personalized treatments must explain relevant procedures, risks, alternatives and material consequences to patients.

3. Mr. X v. Hospital Z (1998) 8 SCC 296

Direct analogous authority.

The Supreme Court examined medical confidentiality and the circumstances in which disclosure of confidential medical information may be justified to protect competing interests.

Legal significance: Genetic and medical information must ordinarily remain confidential, subject to legally recognised exceptions.

4. Jacob Mathew v. State of Punjab (2005) 6 SCC 1

Direct medical-negligence authority.

The Supreme Court explained the principles governing medical negligence and the standard of professional care expected from medical practitioners.

Legal significance: A doctor prescribing personalized medication must exercise reasonable professional competence when interpreting genetic tests and selecting treatment.

5. Kusum Sharma v. Batra Hospital and Medical Research Centre (2010) 3 SCC 480

Direct medical-negligence authority.

The Supreme Court discussed the standards for determining medical negligence and emphasised that a medical professional should not be held negligent merely because another treatment approach was possible.

Legal significance: Personalized treatment decisions should be evaluated against accepted professional standards and the scientific evidence available when the decision was made.

6. Malay Kumar Ganguly v. Dr. Sukumar Mukherjee (2009) 9 SCC 221

Direct medical-negligence authority.

The Supreme Court considered medical negligence, patient safety and the responsibilities of medical practitioners and healthcare institutions.

Legal significance: Hospitals and practitioners providing precision medicine must maintain appropriate clinical standards, documentation and patient-care procedures.

7. Sharda v. Dharmpal (2003) 4 SCC 493

Analogous constitutional and medical-testing authority.

The Supreme Court considered whether a court could direct medical examination in matrimonial proceedings and discussed the relationship between privacy and competing legal interests.

Legal significance: Medical and genetic investigations must be assessed with regard to personal liberty, privacy and the legal justification for the examination.

8. PENALTIES AND LEGAL LIABILITY

Violations of personalized medicine requirements may result in different forms of liability:

Regulatory liability: Unauthorised manufacture, importation or marketing of regulated drugs and medical devices may attract statutory enforcement.

Medical negligence: Incorrect interpretation of genetic results or unreasonable treatment decisions may create professional liability.

Privacy violations: Unlawful disclosure or processing of patient information may attract applicable data-protection consequences.

Clinical-trial violations: Non-compliance with clinical-trial approval, consent and safety requirements may result in regulatory action.

Consumer liability: Misleading claims about diagnostic accuracy or treatment effectiveness may attract consumer-protection remedies.

Contractual liability: Breach of confidentiality and patient-service obligations may result in contractual claims.

9. PRACTICAL COMPLIANCE REQUIREMENTS

Hospitals, pharmaceutical companies, diagnostic laboratories and biotechnology organisations should implement the following measures:

Obtain applicable CDSCO and State Licensing Authority approvals.

Maintain validated genetic-testing procedures.

Establish informed-consent documentation.

Protect genomic and clinical information.

Maintain laboratory quality-control records.

Ensure scientifically supported treatment recommendations.

Establish appropriate adverse-event reporting procedures.

Maintain ethical approval for applicable biomedical research.

Train healthcare professionals in pharmacogenomic interpretation.

Implement patient grievance and medical-negligence prevention procedures.

10. CONCLUSION

Personalized Medicine Regulation Law represents an important development in modern healthcare governance. It combines pharmaceutical regulation, medical-device supervision, genetic-data protection, clinical research ethics and professional medical responsibility.

In India, the Drugs and Cosmetics Act, 1940, New Drugs and Clinical Trials Rules, 2019, Medical Devices Rules, 2017, Digital Personal Data Protection Act, 2023 and applicable ICMR ethical guidelines collectively provide the principal regulatory foundation.

The judgments in Puttaswamy, Samira Kohli, Jacob Mathew and Kusum Sharma establish important legal principles concerning privacy, informed consent and professional responsibility. Although these judgments do not specifically regulate personalized medicine, they provide a judicial foundation for protecting patients receiving genetically tailored and biomarker-based treatments.

Ultimately, effective personalized medicine regulation must balance scientific innovation with patient safety, informed consent, medical accountability, equitable access and protection of genetic information.